menu
    • menu
    [{"orgOrder":0,"company":"Locanabio","sponsor":"Vida Ventures LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"C9orf2 -ALS","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Locanabio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Locanabio \/ Vida Ventures LLC","highestDevelopmentStatusID":"2","companyTruncated":"Locanabio \/ Vida Ventures LLC"},{"orgOrder":0,"company":"Locanabio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Hexanucleotide","graph1":"Neurology","graph2":"Preclinical","graph3":"Locanabio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Locanabio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Locanabio \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Locanabio

    Menu

    Locanabio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Locanabio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Locanabio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Locanabio to Present New Preclinical Data Demonstrating Application of CORRECTx™ Platform for Treating Amyot...

                            Details : C9orf72-related Amyotrophic Lateral Sclerosis (ALS) is a genetic motor neuron disorder caused by a mutation in the C9orf72 gene, resulting in hexanucleotide (G4C2 and C4G2) repeat expansions, targets and destroys hexanucleotide repeats.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 02, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Locanabio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Locanabio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : C9orf2 -ALS

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : Vida Ventures LLC

                            Deal Size : $100.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Locanabio Announces $100 Million Series B Financing to Advance Portfolio of Novel Rnatargeted Gene Therapies

                            Details : Funding supports pre-clinical and clinical development of proprietary RNA-targeting systems delivered via gene therapy for treating genetic diseases such as Huntington’s disease, myotonic dystrophy type 1, genetic ALS, and retinal disease.

                            Brand Name : C9orf2 -ALS

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 14, 2020

                            Lead Product(s) : C9orf2 -ALS

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : Vida Ventures LLC

                            Deal Size : $100.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth